A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2019
At a glance
- Drugs ABBV 105 (Primary) ; Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 04 Jan 2019 Planned End Date changed from 31 Jan 2020 to 15 Jan 2020.
- 26 Nov 2018 Planned End Date changed from 16 Dec 2019 to 31 Jan 2020.
- 15 Oct 2018 Planned End Date changed from 17 Sep 2023 to 16 Dec 2019.